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The pathogenesis of autoimmune pancreatitis is unknown. In the present study we used high-
throughput sequencing with next generation sequencing to identify the candidate genes associated with
AIP. A total of 27 type 1 AIP patients and 30 healthy blood donors were recruited, and DNA samples were
isolated from their mononuclear cells. A high-throughput sequencer with an original custom panel of
1031 genes was used to detect the genetic variants in each sample. Polymorphisms of CACNA1S
(c.4642C4T), rs41554316, rs2231119, rs1042131, rs2838171, P2RX3 (c.195delG), rs75639061, SMAD7
(c.624delC) and TOP1 (c.2007delG), were identiﬁed as candidate genetic variants in patients with type
1 AIP. P2RX3 and TOP1 were signiﬁcantly associated with AIP, even after adjusting bay means of Bon-
ferroni's correction. In addition, we also identiﬁed eight candidate genetic variants that were associated
with the relapse of type 1 AIP, namely: rs1143146, rs1050716, HLA-C (c.759_763delCCCCCinsTCCCG),
rs1050451, rs4154112, rs1049069, CACNA1C (c.5996delC) and CXCR3 (c.630_631delGC). Finally poly-
morphisms of rs1050716 and rs111493987 were identiﬁed as candidate genetic variants associated with
extra-pancreatic lesions in patients with type 1 AIP. These candidates might be used as markers of AIP
susceptibility and could contribute to the pathogenesis of type 1 AIP.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Autoimmune pancreatitis (AIP) is a condition which involves
the chronic inﬂammation of pancreas. It is characterized radi-
ologically by pancreatic enlargement with delayed enhancement
and strictures or narrowing of the main pancreatic duct without
marked upstream dilation; serologically by elevation of serum
immunoglobulin G fraction 4 (IgG4); histologically by lympho-
plasmacytic inﬁltration and ﬁbrosis; and therapeutically by a
dramatic response to steroids [1]. The International Consensus
Criteria for AIP [1] proposed two subtypes of the disease. TheB.V. This is an open access article u
mmunoglobulin G fraction 4;
; DNA, deoxyribonucleic acid;
e polymorphism
jiya).majority of Japanese patients with AIP are classiﬁed as type 1; type
2 AIP is more common in Western countries. Type 1 AIP is also
recognized as a pancreatic manifestation of IgG4-related disease
[2]. Conversely, type 2 AIP is frequently complicated by in-
ﬂammatory bowel diseases [1]. The pathogenesis of type 1 AIP is
unknown but it is considered to be a multifactorial disease which
is associated with genetic and environmental factors. Haruta et al.
reported that a mouse model of AIP was established by persistent
exposure to heat-killed Escherichia coli, suggesting that the chronic
activation of the innate immune system, triggered by intestinal
ﬂora, might cause AIP [3]. In addition, gastric infection by Helico-
bacter pylori was suspected to contribute to the pathogenesis of
AIP, because it shows signiﬁcant homology with human carbonic
anhydrase 2 and the alpha-carbonic anhydrase of Helicobacter
pylori [4].
On the other hand, the genetic factors associated with AIP have
also been reported. Kawa et al. reported that the human leukocytender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with AIP [5]. Subsequently, some of the genes that are associated
with AIP susceptibility were identiﬁed by direct sequencing or a
Taqman assay, these include: ATP-binding cassette sub-family F1
[6], Fc receptor-like 3 [7], cytotoxic T lymphocyte antigen 4 [8],
KCNA3 [9] and PPRS1 [10].
Because multiple genes are usually associated with suscept-
ibility to a multifactorial disease (including unknown genes), a
high-throughput sequence analysis is necessary for the in-
vestigation of genes that confer AIP susceptibility. Oguchi et al.
performed a genome-wide association study to investigate genes
that conferred susceptibility to the triggering of dacryoadenitis or
sialadenitis in Japanese AIP patients; however, they did not show
the genes that were associated with AIP susceptibility [11]. In the
present study, we performed high-throughput sequencing with
next generation sequencing, which targeted more than 1000
genes.2. Material and methods
2.1. Patients and clinical diagnosis
A total of 27 patients with type 1 AIP and 30 healthy blood
donors were consecutively diagnosed and recruited from January
2013 to September 2014 at Asahikawa Medical University or its
afﬁliated institutions. All of the AIP patients and healthy blood
donors were Japanese and provided written informed consent for
inclusion in the high-throughput sequencing analysis. The patients
with a deﬁnite or probable diagnosis of AIP based on the Clinical
Diagnostic Criteria for Autoimmune Pancreatitis 2011 [12] were
enrolled in this study.
2.2. Primer design for custom amplicon sequencing
Because the present study aimed to identify new genetic var-
iants that reﬂect AIP susceptibility, the genes associated with in-
ﬂammatory and autoimmune diseases, hematological and meta-
bolic disorders, and oxidative stress in the gastrointestinal tract,
liver, pancreas and biliary tract were selected as candidates. Con-
sequently, 883 genes that are associated with inﬂammatory and
autoimmune diseases and 209 genes that are associated with
metabolic disorders and oxidative stress were identiﬁed. After
excluding the overlapping genes, 1031 genes were investigated in
the present study. We designed multiple primer sets which tar-
geted 1031 genes (total of 12,609 amplicons) using the Ion Am-
pliSeqTM Designer software program (https://www.ampliseq.
com/browse.action) (Life Technologies, Carlsbad, CA, USA). These
primer sets were provided as ﬁve primer pools. The 12,609 am-
plicons and the targeted lesions are described in Supplemental
Table 1.
2.3. Sample preparation for amplicon sequencing
Peripheral blood samples from each of the patients or healthy
volunteers (HVs) were processed for mononuclear cell isolation by
Ficoll gradient centrifugation. The genomic deoxyribonucleic acid
(DNA) was then extracted and puriﬁed using DNeasy Blood &
Tissue Kits (Qiagen, Venlo, Netherlands). The DNA concentrations
were determined by a QubitTM Fluorometer (Life Technologies,
Carlsbad, CA, USA). The quality of the genomic DNA was assessed
by agarose gel electrophoresis.
2.4. High-throughput sequencing
Using 50 ng of each DNA sample, an ultra-high multiplexpolymerase chain reaction (PCR) was performed and a DNA frag-
ments library (5 primer pools per sample) was generated, using an
Ion AmpliSeqTM Library Kit 2.0 (Life Technologies, Carlsbad, CA,
USA) according to the manufacturer's instructions in order to
perform custom amplicon sequencing. The concentration and
quality of the DNA fragments library was evaluated with an Agi-
lent 2200 Tape station (Agilent Technologies, Santa Clara, CA,
USA). The DNA fragment libraries were then processed for an
emulsion PCR using an Ion OneTouchTM System and an Ion One-
Touch 200 Template Kit v3 (Life Technologies, Carlsbad, CA, USA).
Template-positive Ion SphereTM Particles from the sequencing
reaction were enriched and puriﬁed with an Ion OneTouchTM ES
system (Life Technologies, Carlsbad, CA, USA). The template-posi-
tive Ion SphereTM Particles were then applied on Ion PI™ Chips
(Life Technologies, Carlsbad, CA, USA), and the high throughput
sequencing reaction was carried out using an Ion Proton™ Semi-
conductor sequencer (Life Technologies, Carlsbad, CA, USA).
2.5. The data analysis to detect genetic variants
All of the sequencing data were mapped on a human reference
genome sequence (GRCh37/hg19) using the Torrent Suite Software
program (Life technologies, Carlsbad, CA, USA). The genetic var-
iants were then detected by a Torrent Variant Caller plug-in for the
software program (Life technologies, Carlsbad, CA, USA). In this
program, alleles with frequencies of (the percentage of reads
which possessed a variant) 410%, with a coverage (the number of
reads which had a variant) of 45 and a quality score of 415 were
regarded as signiﬁcant variants. The variant information for each
sample was imported into the CLC Genomics Workbench software
system (CLC bio, Aarhus, Denmark), and Fisher's exact test was
performed to determine the signiﬁcance of the differences among
the samples. Strand bias was deﬁned according to the following
numerical formula: strand bias¼max (VpCm, VmCp)/
VpCmþVmCp (Cp, the number of reads from the plus direction in
the known sequence; Cm, the number of reads from the minus
direction in the known sequence; Vp, the number of reads from
the plus direction in the variant sequence; Vm, the number of
reads from the minus direction in the variant sequence).
2.6. Statistical analysis
In the amplicon sequencing analysis, the candidate genetic
variants were ﬁltered using the P-values determined by Fisher's
exact test. The age between AIP patients and HVs was compared
using the Mann-Whitney U test. P values of o0.05 were con-
sidered to indicate statistical signiﬁcance.
2.7. Ethics statement
The present study was approved by the institutional review
board of Asahikawa Medical University. Written informed consent
was obtained from all of the subjects after a full explanation of the
study.3. Results
3.1. The demographics of the AIP patients and HVs
A total of 57 participants, including 27 patients with type 1 AIP
(male, n¼22; female, n¼5) and 30 HVs (male, n¼17; female,
n¼13) were enrolled in this study. The median age of the AIP
patients at the time of blood collection was 73 years (range: 55–
87). The median age of the HVs at the time of blood collection was
29.5 years (range: 22–49). The HVs were signiﬁcantly younger
Table 1
Status information of the patients with AIP and HVs.
AIP HVs P value
Gender; Male 22 (81.5%) 17 (56.7%) 0.0522
Female 5 (18.5%) 13 (43.3%)
Median age (range) 73 (55–87) 29.5 (20–49) o0.01
Comorbidity Diabetes mellitus 13 (48.1%) 0 (0%) o0.01
Hypertension 9 (33.3%) 3 (10%) 0.0489
Hyperlipidemia 9 (33.3%) 1 (3.3%) o0.01
Asthma bronchiale 4 (14.8%) 1 (3.3%) 0.1791
Cataract 4 (14.8%) 0 (0%) 0.0444
Hyperuricemia 2 (7.4%) 0 (0%) 0.2199
Heart failure 2 (7.4%) 0 (0%) 0.2199
Aortic aneurysm 2 (7.4%) 0 (0%) 0.2199
Allergic rhinitis 1 (3.7) 3 (10%) 0.6135
Past history Appendectomy 7 (25.9%) 1 (3.3%) 0.021
Maligancy 3 (11.1%) 0 (0%) 0.10
Biliary stone 3 (11.1%) 0 (0%) 0.10
Urolithiasis 0 (0%) 2 (6.7%) 0.4925
Pancretic disease 0 (0%) 0 (0%) 1.0
Table 2
Clinical ﬁndings of the patients with AIP.
The median age at the time of onset (range) 64 years old (50–82)
Obstructive Jaundice 10/27 (37%)
Enlargement of the pancreas [Diffuse: Focal] 25/27 (92.6%) [15/25(60%):
10/25(40%)]
Serum IgG4 4135 mg/dl 25/26 (96.2%)
Median(range) 462 (57–3245)
Serum IgG 41800 15/27 (55.6%)
Median(range) 1857 (1327–6348)
Hypergammaglobulinemia 17/26 (65.4%)
Anti-nuclear antibody 11/25 (44%)
Rheumatoid factor 1/19 (5.3%)
Pathological diagnosis 4/26 (15.4%)
Extra-pancreatic lesions Sclerosing
cholangititis
18/27 (66.7%) 17/18 (94.4%)
Sialadenitis 2/18 (11.1%)
Dacryoadenitis 3/18 (16.7%)
Interstitial nephritis 2/18 (11.1%)
Swelling of lymph
node
8/18 (44.4%)
Treatment of steroids 24/27 (88.9%)
Relapse 7/27 (25.9%)
S. Fujibayashi et al. / Biochemistry and Biophysics Reports 6 (2016) 76–8178than the AIP patients at the time of blood collection (po0.01),
while the difference in the gender ratio of the two groups was not
statistically signiﬁcant (Table 1). The comorbidities of the patientsTable 3
Identiﬁed candidates of genetic variants associated with type 1 AIP.
Chr Position type (SNP rs) A Frequency Candidate
AIP(%)
N¼27
HVs(%)
N¼30
1 201,016,269 SNP (new) G4A 7 (25.9) 0(0) CACNA1S
6 29,912,315 SNP
(rs41554316)
A4C 11 (40.7) 4(13.3) HLA-A
6 29,912,856 SNP (rs2231119) A4T 23 (85.2) 18(60) HLA-A
6 33,048,602 SNP (rs1042131) C4A 24 (88.9) 18(60) HLA-DPB1
7 151,945,051 SNP
(rs2838171)
A4G 12 (44.4) 2(6.7) MLL3
11 57,114,093 Deletion G4- 11 (40.7) 0(0) P2RX3
15 78,789,672 SNP
(rs75639061)
A4G 9 (33.3) 3(10) IREB2
18 46,474,797 Deletion G4- 5 (18.5) 0(0) SMAD7
20 39,750,392 Deletion G4- 12 (44.4) 0(0) TOP1
Chr: Chromosome, SNP: single nucleotide polymorphism, A: Allele, AIP: autoimmune p
value: P value after adjustment by Bonferroni's correction.in both of the groups are shown in Table 1; the frequency of dia-
betes mellitus (AIP, n¼13 [48.1%]; HVs, n¼0 [0%], po0.01), hy-
pertension (AIP, n¼9 [33.3%]; HVs, n¼3 [10%], p¼0.0498), hy-
perlipidemia (AIP, n¼9 [33.3%]; HVs, n¼1 [3.3%], po0.01) and
cataracts (AIP, n¼4 [14.8%]; HVs, n¼0 [0%], p¼0.0444) was sig-
niﬁcantly higher in the AIP patients than in the HVs. Furthermore,
a signiﬁcantly higher percentage of the AIP patients had a past
history of appendectomy for appendicitis than the HVs (AIP, n¼7
[25.9%]; HVs, n¼1 [3.3%], p¼0.021).
The median age at the time of AIP onset was 64 years (range:
50–82 years), which was in line with previous reports [13]. Ob-
structive jaundice, enlargement of the pancreas and irregular
narrowing of the main pancreatic duct was observed in 10 (37%),
25 (93%; focal, n¼10; diffuse, n¼15) and 27 (100%) of the AIP
patients, respectively. The elevation of serum IgG4 (more than
135 mg/dl) and serum IgG (more than 1800 mg/dl) was observed
in 25 (96%) and 15 patients (56%), respectively. The median serum
IgG4 and IgG values were 462 mg/dl (range: 57–3245 mg/dl) and
1857 mg/dl (range: 1327–6348 mg/dl), respectively. Hy-
pergammaglobulinemia, anti-nuclear antibody and rheumatoid
factor were detected in 17 (65%), 11 (44%) and one (5%) patient,
respectively.
Although pathological examinations were performed in 26
patients, only four patients were pathologically diagnosed with
AIP (15.4%). Extra-pancreatic lesions (n¼18, 67%), sclerosing cho-
langititis (n¼17, 94.4%), sialadenitis (n¼2, 11.1%), dacryoadenitis
(n¼3, 16.7%), interstitial nephritis (n¼2, 11.1%) and lymph node
swelling (n¼8, 44.4%) were observed. Prednisolone was ad-
ministered to 24 patients (89%), all of whom showed radiological
improvement. Seven patients (29%) relapsed during dose tapering
or after the termination of steroid therapy (Table 2).
3.2. The candidate genetic variants identiﬁed in patients with type
1 AIP
DNA was isolated from mononuclear cells in the blood samples
from the 27 AIP patients and the 30 HVs. The quality check
showed that all of the samples were of sufﬁcient quality to allow
the genetic variants to be analyzed. These DNA samples were
ampliﬁed using 5 primer pools and were subsequently sequenced
using a high-throughput sequencer.
The mean depth of coverage, number of variants and mapped
reads and ratio of output reads/mapped reads (on target) are
shown in Supplemental Table 2. The mean depth of coverage was
241.70 (SD: 206.53) and 225.28 (SD: 142.18) in the HVs and the AIP
patients, respectively. The mean on-target value was 96.02% (SD:Gene Gene description P value (Pc value)
Calcium channel in skeleton muscle 0.0034 (0.85)
The class 1 major histocompatibility complex 0.020 (1)
The class 1 major histocompatibility complex 0.033 (1)
The class 2 major histocompatibility complex 0.014 (1)
Methylation of histon, Altering antibody effector
function
0.0011 (0.20)
Purinergic receptor of pain perception 0.000071 (0.015)
Regulation of iron homeostasis 0.033 (1)
Inhibitory protein of TGFB1 signaling 0.019 (0.83)
DNA topoisomerases 1 catalyze the breaking DNA 0.000025 (0.0010)
ancreatitis, HV: Healthy volunteer, TGFB1: Transforming growth factor beta-1, Pc
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S. Fujibayashi et al. / Biochemistry and Biophysics Reports 6 (2016) 76–81 790.4764) and 95.30% (SD: 0.8082) in the HVs and AIP patients, re-
spectively. Therefore, the coverage in this study was thought to be
sufﬁcient [14].
We ﬁrst proﬁled the differences in the frequencies of genetic
variants in the AIP patients and the HVs. Among a total of 4206
variants, 16 variants were extracted by Fishers' exact test (Po0.05)
as signiﬁcant candidates, when we focused on the variants with
amino-acid modiﬁcation. In this study, we set the cut-off value for
the strand bias at o0.60, and 11 of variants remained as candi-
dates. Among these 11 candidates, there were seven known single
nucleotide polymorphisms (SNPs, rs4973986, rs41554316,
rs2231119, rs1042131, rs2838171, rs75639061, rs17576) and four
new variants (CACNA1S (c.4642C4T), P2RX3 (c.195delG), SMAD7
(c.624delC), TOP1 (c.2007delG)). Rs4973986 and rs17576 were
excluded because almost all Japanese individuals are known to
have these variants [15]. Finally, we identiﬁed nine candidate
variants associated with type 1 AIP (Table 3).
3.3. The candidate genetic variants identiﬁed as being associated
with the relapse of type 1 AIP
AIP relapse occurred in seven patients. Next, we proﬁled the
difference in the frequencies of genetic variants in the AIP patients
with/without relapse. Among a total 2631 variants, 13 variants
were extracted as signiﬁcant candidates by Fishers' exact test
(Po0.05) after excluding the variants without amino-acid mod-
iﬁcations in which the strand bias was 40.60. Among these 13
candidates, there were ten known single nucleotide polymorph-
isms (rs1143146, rs1050716, rs1050451, rs41544112, rs1049069,
rs328, rs238238, rs16027, rs2108622, rs2071747) and three new
variants (HLA-C (c.759_763delCCCCCinsTCCCG), CACNA1C
(c.5996delC), CXCR3 (c.630_631delGC)). Rs328, rs238238, rs16027,
rs2108622 and rs2071747 were excluded because almost all Japa-
nese individuals are known to have these variants [15]. Finally we
identiﬁed eight candidate variants associated with the relapse of
AIP (Table 4).
3.4. The identiﬁed candidate genetic variants associated with extra-
pancreatic lesions of type 1 AIP
Among the 24 AIP patients, 18 had extra-pancreatic lesions.
Finally, we investigated the difference in the frequencies of genetic
variants in the AIP patients with/without extra-pancreatic lesions.
Among a total 3319 variants, ﬁve known SNPs were extracted as
signiﬁcant candidates by Fishers' exact test (po0.05) after ex-
cluding the variants without amino-acid modiﬁcation or in which
the strand bias was 40.60, we identiﬁed rs2228001, rs78422529/
rs116229259/rs17413706/rs1050716, rs111493987, rs3736032 and
rs1800470. Rs2228001, rs3736032 and rs1800470 because they are
known to exist in almost all Japanese individuals [15]. Finally, we
identiﬁed two known SNPs as candidate gene variants associated
with extra-pancreatic lesions (Table 5).4. Discussion
The high-throughput sequencing analysis using next genera-
tion sequencing identiﬁed nine, eight and two candidate variants
associated with the development of type 1 AIP, AIP relapse and
extra-pancreatic lesions in type 1 AIP patients, respectively. Most
of the previous studies to investigate the genes associated with
susceptibility to AIP [6–10] did not involve comprehensive ana-
lyses, rather, they focused on target lesions that were reported to
be associated with autoimmune disease or which were extracted
by a microsatellite genotyping analysis. This might have been
caused by the classical sequencing procedures. In contrast, our
Table 5
Identiﬁed candidates of genetic variants associated with extra-pancreatic lesions of type 1 AIP.
Chr Position type (SNP rs) A Frequency Candidate gene Gene description P value (Pc
value)
with EPL(%)
N¼18
w/o EPL(%)
N¼9
6 31,238,230 SNP (rs1050716) G4C 14 (77.8) 3 (33.3) HLA-C The class 1 major histocompatibility complex 0.034
7 151,935,871 SNP
(rs111493987)
C4A 14 (77.8) 4 (13.3) MLL3 Methylation of histon, Altering antibody effector
function
0.034
Chr: Chromosome, SNP: single nucleotide polymorphism, A: Allele, EPL: extra-pancreatic lesions, w/o: without.
S. Fujibayashi et al. / Biochemistry and Biophysics Reports 6 (2016) 76–8180study used high-throughput sequencing. A recent genome-wide
association study did not reveal the genes that are associated with
AIP susceptibility [11]. The present study is therefore the ﬁrst
comprehensive analysis of the genes related to AIP susceptibility.
AIP is considered to be an autoimmune disorder. Indeed, car-
bonic anhydrase, lactoferrin, pancreatic secretory trypsin inhibitor,
amylase-alpha, ubiquitin-protein ligase E3, SPINK and TRY1 have
been identiﬁed as the autoimmune antigens associated with AIP
[16,17]. We therefore hypothesized that there might be com-
monality in the genetic background of AIP patients with regard to
the genes associated with the immune system.
Among the nine candidate genetic variants that were found to
be associated with type 1 AIP, P2RX3 (c.195delG) and TOP1
(c.2007delG) showed a highly signiﬁcant association with AIP,
even after adjustment by Bonferroni's correction. P2RX3, which
constitutes a positive autocrine signal for insulin release in the
pancreatic beta cells [18,19] and contributes to the pancreatic pain
caused by chronic pancreatitis [20], is associated with the immune
system. A recent study reported that an enlarged spleen, which
corresponds to an increase in the numbers of lymphocytes and
macrophages, and hypocellularity of the thymus and bone marrow
were observed in P2RX2 and P2RX3 knockout mice, suggesting
that they resulted from compensatory changes in a compromised
immune system [21]. TOP1, which encodes DNA topoisomerase
1 that catalyzes the breaking and rejoining of single-strand DNA
and which functions normally during transcription [22], is also
associated with various autoimmune diseases, including scler-
oderma, systemic lupus erythematosus and rheumatoid arthritis
[23,24]. Besides these two candidates, CACNA1 S and MLL3 also
play a role in the immune system. CACNA1S, which encodes the
L-type calcium channel alpha 1 subunit, is expressed on T-lym-
phocytes and regulates the calcium current, which can induce the
activation of T cell antigen receptors [25]. MLL3 forms a complex
with MLL4 and subsequently initiates the transcription of down-
stream switch regions at the immunoglobulin heavy-chain locus in
B-lymphocytes, leading to defective immunoglobulin class
switching [26]. Although, these candidates might contribute to the
pathogenesis of AIP, the inﬂuence of these candidate genetic var-
iants on the immune system remains unknown. Further studies to
investigate the relationship between these candidate genetic var-
iants and the autoantibodies associated with AIP are needed.
Transforming growth factor beta (TGF-β) is known to be an
important regulating factor in the maintenance of immune
homeostasis. A previous study suggested that a loss of TGF-β
signaling contributed to AIP [27]. In the present study, we iden-
tiﬁed a deletion in SMAD7 as a candidate genetic factor associated
with the pathogenesis of AIP. Thus SMAD7 could be suitable
marker of AIP; however, it is necessary to further evaluate TGF-β
signaling under the genetic condition of SMAD7 deletion
(c.624delC).
We also identiﬁed eight candidate genetic variants that are
associated with the relapse of type 1 AIP. Six candidates were
HLAs, which are closely associated with some autoimmune dis-
eases, including AIP [5]. In particular, HLA-DQB1 was reported tobe associated with the relapse of AIP in a Korean study [28], which
suggests that HLA-DQB1 could be a strong candidate gene asso-
ciated with susceptibility to AIP relapse.
In this study, we also explored the genes that were associated
with susceptibility to extra-pancreatic lesions, including sclerosing
cholangititis, sialadenitis, dacryoadenitis, interstitial nephritis and
lymph node swelling, and identiﬁed two candidates. Oguchi et al.
performed a genome-wide association study and extracted ten
candidates associated with susceptibility to dacryoadenitis or
sialadenitis in the Japanese patients with AIP, while no genes as-
sociated with all extra-pancreatic lesions was identiﬁed [11]. In
this study, because sialadenitis and dacryoadenitis were only ob-
served in two and three patients, respectively, we could not
identiﬁed the genes that were speciﬁcally associated with da-
cryoadenitis or sialadenitis susceptibility in AIP patients. Indeed,
AIP is a rare disease with a prevalence rate of 4.6 per 100,000
population and an annual incidence rate of 1.4.per 100,000 po-
pulation [13]. A nationwide or worldwide study will therefore be
needed to validate the candidates associated with susceptibility to
AIP.5. Conclusion
In the present study, we performed a high-throughput se-
quencing analysis using next generation sequencing to compre-
hensively investigate 1031 genes. Our analysis identiﬁed nine,
eight and two candidate variants associated with type 1 AIP, the
relapse of AIP and extra-pancreatic lesions, respectively. These
candidates might be used as markers for the diagnosis of AIP and
extra-pancreatic lesions as well as for predicting the relapse of AIP.Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.bbrep.2016.03.005.References
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